These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19383340)

  • 1. Will the innovative medicines initiative really deliver innovative medicines?
    Wilkinson E
    Mol Oncol; 2008 Oct; 2(3):203-5. PubMed ID: 19383340
    [No Abstract]   [Full Text] [Related]  

  • 2. Who can pay for innovative medicines?
    Decramer S; Decramer M
    Eur Respir J; 2013 Mar; 41(3):495-6. PubMed ID: 23456929
    [No Abstract]   [Full Text] [Related]  

  • 3. US drug manufacturers set up joint testing group.
    Davies E
    BMJ; 2012 Sep; 345():e6394. PubMed ID: 23002149
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug Regulation and Pricing--Can Regulators Influence Affordability?
    Eichler HG; Hurts H; Broich K; Rasi G
    N Engl J Med; 2016 May; 374(19):1807-9. PubMed ID: 27168431
    [No Abstract]   [Full Text] [Related]  

  • 5. Will lower drug prices jeopardize drug research? A policy fact sheet.
    Light DW; Lexchin J
    Am J Bioeth; 2004; 4(1):W1-4. PubMed ID: 15035915
    [No Abstract]   [Full Text] [Related]  

  • 6. The Innovative Medicines Initiative: a pre-competitive initiative to enhance the biomedical science base of Europe to expedite the development of new medicines for patients.
    Hunter AJ
    Drug Discov Today; 2008 May; 13(9-10):371-3. PubMed ID: 18468553
    [No Abstract]   [Full Text] [Related]  

  • 7. Outlook for the next 5 years in drug innovation.
    Berggren R; Møller M; Moss R; Poda P; Smietana K
    Nat Rev Drug Discov; 2012 Jun; 11(6):435-6. PubMed ID: 22653208
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibiotics: the changing regulatory and pharmaceutical industry paradigm.
    Bax R; Green S
    J Antimicrob Chemother; 2015 May; 70(5):1281-4. PubMed ID: 25634991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical pricing conundrum: time to get rid of it?
    Garattini L; Padula A
    Eur J Health Econ; 2018 Nov; 19(8):1035-1038. PubMed ID: 30030646
    [No Abstract]   [Full Text] [Related]  

  • 10. Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.
    Beatty PA; Laking GR
    J Oncol Pract; 2015 May; 11(3):249-51. PubMed ID: 25829524
    [No Abstract]   [Full Text] [Related]  

  • 11. No immediate pain relief for the pharmaceutical industry.
    Ahlborn H; Henderson S; Davies N
    Curr Opin Drug Discov Devel; 2005 May; 8(3):384-91. PubMed ID: 15892254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Foreign free riders and the high price of US medicines.
    Light DW; Lexchin J
    BMJ; 2005 Oct; 331(7522):958-60. PubMed ID: 16239695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience.
    Dunlop WCN; Staufer A; Levy P; Edwards GJ
    Health Policy; 2018 May; 122(5):528-532. PubMed ID: 29567205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impressive gains with innovative medicines.
    Chin B
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):65. PubMed ID: 25129907
    [No Abstract]   [Full Text] [Related]  

  • 15. The Importance of Economic Trade-offs in Cancer Drug Pricing.
    Fonseca R; Peneva D; Clancy Z; Abouzaid S; Jena AB
    Mayo Clin Proc; 2018 Aug; 93(8):976-979. PubMed ID: 29945732
    [No Abstract]   [Full Text] [Related]  

  • 16. The economics of resistant pathogens and antibiotic innovation.
    McKellar MR; Chernew ME; Fendrick AM
    Am J Manag Care; 2014 Mar; 20(3):193-7. PubMed ID: 24884749
    [No Abstract]   [Full Text] [Related]  

  • 17. Precompetitive activity to address the biological data needs of drug discovery.
    Sidders B; Brockel C; Gutteridge A; Harland L; Jansen PG; McEwen R; Michalovich D; Seidel H; Weiss B; Williams-Jones B; Woodwark M
    Nat Rev Drug Discov; 2014 Feb; 13(2):83-4. PubMed ID: 24481293
    [No Abstract]   [Full Text] [Related]  

  • 18. European initiative towards quality standards in education and training for discovery, development and use of medicines.
    Klech H; Brooksbank C; Price S; Verpillat P; Bühler FR; Dubois D; Haider N; Johnson C; Lindén HH; Payton T; Renn O; See W
    Eur J Pharm Sci; 2012 Apr; 45(5):515-20. PubMed ID: 22178534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
    John JE
    Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
    [No Abstract]   [Full Text] [Related]  

  • 20. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine.
    Tsimberidou AM; Ringborg U; Schilsky RL
    Am Soc Clin Oncol Educ Book; 2013; ():118-25. PubMed ID: 23714475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.